Who are Vonoprazan+tetracycline+furazolidone 7 days's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vonoprazan+tetracycline+furazolidone 14 days, Vonoprazan+amoxicillin+furazolidone 7 days.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vonoprazan-tetracycline-furazolidone-7-days.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Vonoprazan+tetracycline+furazolidone 7 days — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vonoprazan+tetracycline+furazolidone 7 days (Vonoprazan+tetracycline+furazolidone 7 days) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H. pylori eradication therapy (triple therapy). Area: Gastroenterology / Infectious Disease.

marketed H. pylori eradication therapy (triple therapy) Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Vonoprazan+tetracycline+furazolidone 7 days (Vonoprazan+tetracycline+furazolidone 7 days) — Xijing Hospital of Digestive Diseases. This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan), inhibiting bacterial protein synthesis (tetracycline), and providing additional antimicrobial activity (furazolidone).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vonoprazan+tetracycline+furazolidone 7 days TARGET	Vonoprazan+tetracycline+furazolidone 7 days	Xijing Hospital of Digestive Diseases	marketed	H. pylori eradication therapy (triple therapy)
Vonoprazan+tetracycline+furazolidone 14 days	Vonoprazan+tetracycline+furazolidone 14 days	Xijing Hospital of Digestive Diseases	marketed	H. pylori eradication therapy (triple therapy)
Vonoprazan+amoxicillin+furazolidone 7 days	Vonoprazan+amoxicillin+furazolidone 7 days	Xijing Hospital of Digestive Diseases	marketed	H. pylori eradication therapy (triple therapy)	H. pylori (bacterial pathogen); vonoprazan targets H+/K+-ATPase; amoxicillin targets penicillin-binding proteins; furazolidone targets bacterial DNA/protein synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H. pylori eradication therapy (triple therapy) class)

Xijing Hospital of Digestive Diseases · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vonoprazan+tetracycline+furazolidone 7 days — Competitive Intelligence Brief. https://druglandscape.com/ci/vonoprazan-tetracycline-furazolidone-7-days. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab